The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis

Acta Neurologica Scandinavica

Volumn 129, Issue 1, 2014, Pages 27-31

  Moller M ^a   Sondergaard H B ^a   Koch Henriksen, N ^a,b   Sorensen, P S ^a   Sellebjerg, F ^a   Oturai, A B ^a  

^a Rigshospitalet   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Demyelinating diseases; Immunology; Molecular genetics; Multiple sclerosis

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MITOXANTRONE; NATALIZUMAB;

ADULT; ARTICLE; BLOOD SAMPLING; CELL SURFACE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RELAPSE; SCORING SYSTEM; WILD TYPE;

DEMYELINATING DISEASES; IMMUNOLOGY; MOLECULAR GENETICS; MULTIPLE SCLEROSIS;

ADULT; ALLELES; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INTEGRIN ALPHA4BETA1; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; RECEPTORS, CCR5; SEQUENCE DELETION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84888881063     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12145     Document Type: Article

References (31)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
2. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999;96:6873-8.
3. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-21.
4. Sorensen TL, Tani M, Jensen J et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-15.
5. Trebst C, Konig F, Ransohoff R, Bruck W, Stangel M. CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions. Mult Scler 2008;14:728-33.
6. Weber C, Weber KS, Klier C et al. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood 2001;97:1144-6.
7. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-7.
8. Kantarci OH, Morales Y, Ziemer PA et al. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol 2005;169:137-43.
9. Schreiber K, Otura AB, Ryder LP et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler 2002;8:295-8.
10. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000;102:98-106.
11. van Veen T, Nielsen J, Berkhof J et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol 2007;190:157-64.
12. Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology 2003;61:238-40.
13. Barcellos LF, Schito AM, Rimmler JB et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 2000;51:281-8.
14. Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997;58:52-9.
15. Favorova OO, Andreewski TV, Boiko AN et al. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology 2002;59:1652-5.
16. Gade-Andavolu R, Comings DE, MacMurray J et al. Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet Med 2004;6:126-31.
17. Pulkkinen K, Luomala M, Kuusisto H et al. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol Scand 2004;109:342-7.
18. Silversides JA, Heggarty SV, McDonnell GV, Hawkins SA, Graham CA. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler 2004;10:149-52.
19. Proudfoot AE, Power CA, Schwarz MK. Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 2010;19:345-55.
20. Roxburgh RH, Seaman SR, Masterman T et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-51.
21. Rothhammer V, Heink S, Petermann F et al. Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE. J Exp Med 2011;208:2465-76.
22. Glatigny S, Duhen R, Oukka M, Bettelli E. Cutting edge: loss of alpha4 integrin expression differentially affects the homing of Th1 and Th17 cells. J Immunol 2011;187:6176-9.
23. Wipfler P, Oppermann K, Pilz G et al. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. Mult Scler 2011;17:16-23.
24. Harrer A, Pilz G, Einhaeupl M et al. Lymphocyte subsets show different response patterns to in vivo bound natalizumab-a flow cytometric study on patients with multiple sclerosis. PLoS ONE 2012;7:e31784.
25. Vennegoor A, Rispens T, Strijbis EM et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013;19:593-600.
26. Moreno B, Jukes JP, Vergara-Irigaray N et al. Systemic inflammation induces axon injury during brain inflammation. Ann Neurol 2011;70:932-42.
27. Reboldi A, Coisne C, Baumjohann D et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009;10:514-23.
28. Krakauer M, Sørensen PS, Sellebjerg F. CD4+ T memory cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J Neuroimmunol 2006;181:161-9.
29. Sellebjerg F, Kristiansen TB, Wittenhagen P et al. Chemokine receptor CCR5 in interferon-treated multiple sclerosis. Acta Neurol Scand 2007;115:413-8.
30. Sellebjerg F, Krakauer M, Limborg S et al. Endogenous and recombinant type I interferons and disease activity in multiple sclerosis. PLoS ONE 2012;7:e35927.
31. Hesse D, Krakauer M, Lund H et al. Breakthrough disease during interferon β therapy in MS: no signs of impaired biologic response. Neurology 2010;74:1455-62.